EUVIMEDEUVIMED entdecken
Crossref

GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency

Yecheng Tang, Mingming Zhang, Yuxin Fang, Qingjun Li, Yingqi Song, Chunquan Sheng iD, Guoqiang Dong iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c00367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Yecheng Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325000, China. Hauptthemen laut MEDLINE: Von Hippel-Lindau Tumor Suppressor Protein, Transcription Factors, Ubiquitin-Protein Ligases, Cell Cycle Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the identification of over 600 E3 ligases, current proteolysis-targeting chimeras (PROTACs) predominantly rely on CRBN and VHL. Recently, GID4, a substrate receptor of the CTLH E3 ligase complex, emerged as a promising alternative handle. Herein, through structural simplification of a known GID4 ligand, we developed compound a11 as a potent GID4-recruiting BRD4 degrader. Compound a11 induced efficient, selective, and GID4-dependent BRD4 degradation via the ubiquitin-proteasome pathway (DC50 = 0.21 ± 0.04 μM). Crucially, a11 maintained degradation activity in VHL- and CRBN-deficient models, exhibiting superior antiproliferative effects in VHL-deficient 786-O renal cell carcinoma (RCC) cells. In vivo, a11 achieved significant tumor growth inhibition (TGI = 67%) in a 786-O xenograft model, outperforming corresponding CRBN- and VHL-recruiting analogs. This platform's broader utility was further confirmed by successfully degrading VEGFR2. Overall, this study establishes GID4 as a viable PROTAC handle with therapeutic potential in renal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Von Hippel-Lindau Tumor Suppressor ProteinTranscription FactorsUbiquitin-Protein LigasesCell Cycle ProteinsAntineoplastic AgentsAdaptor Proteins, Signal TransducingHumansBromodomain Containing ProteinsAnimalsProteolysis Targeting ChimeraCell Line, TumorMiceProteolysisCarcinoma, Renal CellKidney NeoplasmsCell ProliferationMice, NudeDrug Resistance, Neoplasm

Substanzen

Von Hippel-Lindau Tumor Suppressor ProteinBromodomain Containing ProteinsProteolysis Targeting ChimeraBRD4 protein, humanTranscription FactorsVHL protein, humanUbiquitin-Protein LigasesCell Cycle ProteinsCRBN protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325000, China.
  • The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Second Military Medical University (Naval Medical University), 325 Guohe Road, Shanghai 200433, China.
  • School of Pharmacy, Wannan Medical University, Wuhu 241002, China.
  • Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China.

ORCID-Profile: Chunquan Sheng, Guoqiang Dong

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Tang, Y., Zhang, M., Fang, Y., Li, Q., Song, Y., Sheng, C., & Dong, G. (2026). GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c00367

Vancouver

Tang Y, Zhang M, Fang Y, Li Q, Song Y, Sheng C, et al. GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c00367

BibTeX
@article{Tang2026,
  author = {Tang, Yecheng and Zhang, Mingming and Fang, Yuxin and Li, Qingjun and Song, Yingqi and Sheng, Chunquan and Dong, Guoqiang},
  title = {GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c00367}
}
Kostenlos starten →